Festival of Biologics 2026 Exhibitors
Oct 13–15, 2026 Basel, Switzerland ~3k attendees Website
188 organizations exhibit at Festival of Biologics 2026 — 175 suppliers and service providers, 9 drug developers and 4 academic, government and non-profit bodies. 40 of them also present on the scientific program, with 79 presentations between them. Most represented: Novartis (29 on the program), Lonza (6 on the program), YUMAB (3 on the program). 188 of them have their own page in this guide. As of Sep 26, 2026.
Topic
Top represented
Showing 1–30 of 188 organizations
| Organization | Festival of Biologics 2026 Attendance |
|---|---|
Novartis Basel, Switzerland | |
Global pharmaceutical company whose contract manufacturing arm offers CDMO services for biologics, small molecules, cell and gene therapy, and fill-finish. | Booth Exhibiting at Booth 185 Keynote Tue Oct 13 09:10 Biotechnology, the Renaissance How advances in biology, AI and new treatment types are converging to change what medicine can do for patients. Chair Tue Oct 13 11:25 Chair Tue Oct 13 11:25 Chair Tue Oct 13 11:25 Talk Tue Oct 13 11:30 Panel Tue Oct 13 12:20 Chair Tue Oct 13 14:05 Talk Tue Oct 13 14:50 Intensified Upstream Processing: Fed‑Batch and Perfusion Options for Robust Scale-Up Ways to get more protein from cell cultures by feeding them steadily or continuously, and how to scale that up reliably. Talk Tue Oct 13 15:10 Panel Tue Oct 13 15:10 Panel Discussion: From Research to GMP: Making MSC Manufacturing Reproducible at Scale How to grow mesenchymal stromal cells, a kind of stem cell, the same way batch after batch as production scales up. Talk Tue Oct 13 15:30 Chair Tue Oct 13 16:45 Panel Tue Oct 13 17:30 Panel Discussion: Next Generation Antibody Formats Where antibody drug design is heading, from two-target antibodies and antibody-drug conjugates to AI's role in engineering them. Talk Tue Oct 13 17:30 What AI can do – or not – in Patient Engagement What AI can and cannot do when drug developers involve patients in research, and how to measure whether that involvement helps. Chair Wed Oct 14 11:25 Chair Wed Oct 14 11:25 Talk Wed Oct 14 12:10 Talk Wed Oct 14 12:30 Bovine AAV – a promising vector for pulmonary gene therapy Early results from using a cattle adeno-associated virus to deliver gene therapy to the lungs, including how immune systems recognise it. Talk Wed Oct 14 12:30 Chair Wed Oct 14 14:05 Talk Wed Oct 14 14:30 Commercial Considerations for CAR-T Therapy: Lessons Learned from Recent Blockbusters What makes CAR-T cancer therapies hard to sell worldwide, from complex manufacturing and shipping to getting treatment centres and payers ready. Talk Wed Oct 14 15:30 When the Target Moves: Building Robust DSP Through Science, Monitoring, and Learning Why purification steps that once worked can start failing when the material feeding them changes, and how monitoring catches that early. Chair Wed Oct 14 16:45 Chair Wed Oct 14 16:45 Talk Wed Oct 14 16:50 Talk Wed Oct 14 17:30 Protein Quality as a Critical Factor in Target Interference Assessment for Bioanalytical Assays How the quality of a lab-made protein can distort tests that check whether patients make antibodies against a biologic drug. Talk Wed Oct 14 17:50 An Oligonucleotide Program in Late-Stage Clinical Trials Lessons from keeping an anti-drug antibody test working for a cholesterol-lowering siRNA drug through late trials and a handover to a partner lab. Keynote Thu Oct 15 09:05 From Strategy to Delivery: Aligning Bioanalytical Innovation and Execution Across Clinical Phases How to decide what to measure, when and why, as biologic drugs move from early studies into late-stage clinical trials. Talk Thu Oct 15 09:40 Chair Thu Oct 15 11:15 Chair Thu Oct 15 11:15 |
Lonza Basel, Switzerland | |
Contract development and manufacturing partner for biologics, cell and gene therapies and small molecules. | Booth Exhibiting at Booth 450 Talk Tue Oct 13 17:10 De-risking Lyophilization Scale-Up Using predictive models How computer models of freeze-drying can predict what happens at full manufacturing scale, cutting experiments and the risk of a failed transfer. Keynote Wed Oct 14 09:55 From Experimentation to Prediction: How Data-Driven Innovation is Forging Predictability Across Biologics Development and Precision Biomanufacturing Why biologics developers still decide by trial and error, and how treating every program as shared learning could make outcomes more predictable. Bioprocessing & manufacturingAI & computational design Talk Wed Oct 14 12:30 Accelerating CHO Cell Line Development Through Next-Generation Expression System Design How improved cell engineering, promoter design and selection methods shorten the path from DNA to a cell line that makes a drug. Talk Wed Oct 14 14:30 Beyond mAbs: accelerated Gene-to-IND development for bispecifics, Fc-fusions and high-concentration biologics Faster routes from DNA to first clinical trials for complex antibody drugs, and the problems they create in making, purifying and formulating them. |
YUMAB Braunschweig, Germany | |
Antibody discovery and development company generating fully human antibodies for partners from human antibody libraries. | Booth Exhibiting (no floor booth listed) Chair Tue Oct 13 14:05 Talk Wed Oct 14 12:10 Advancing Antibody Discovery Through Paired Libraries Capturing millions of single B cells to build antibody libraries that keep each cell's natural heavy and light chain pairing. Keynote Thu Oct 15 09:55 Hunting Hidden Targets: Developing Highly Specific Antibodies Against Peptide-HLA Complexes Antibodies that recognise protein fragments from inside cells displayed on the cell surface, and how to stop them binding the wrong targets. |
Pharmaron Beijing, China | |
R&D service company supporting biologics from discovery to commercialization with integrated laboratory, preclinical, development, manufacturing and regulatory services. | Booth Exhibiting at Booth 406 Talk Wed Oct 14 17:10 Successful CMC Development & Manufacturing is Built on Highly Effective Partnerships Why complex biologic drugs rely on close partnerships in manufacturing and quality control to move from preclinical work to clinical supply. Chair Thu Oct 15 08:55 Chair Thu Oct 15 11:15 |
Develops therapeutic antibodies and antibody-drug conjugates for cancer. | Booth Exhibiting (no floor booth listed) Talk Wed Oct 14 12:30 A Novel Pan-Cancer TRPV6-Targeted Therapy Driving Antitumor Activity Through Ion Channel Modulation Why an ion channel that helps tumors grow may be a drug target in many cancers, with lab and animal tests of a therapy. |
FB FairJourney Biologics Porto, Portugal | |
Antibody discovery and engineering partner working on behalf of biotech and pharma clients. | Booth Exhibiting (no floor booth listed) Panel Tue Oct 13 17:30 Panel Discussion: Next Generation Antibody Formats Where antibody drug design is heading, from two-target antibodies and antibody-drug conjugates to AI's role in engineering them. |
Genedata Basel, Switzerland | |
Makes software combining science, technology and AI to digitalize and make use of biopharma research data. | Booth Exhibiting (no floor booth listed) Keynote Tue Oct 13 10:20 Connecting Data, Science, and AI for Lab-in-the-Loop Biologics Research How pairing AI with lab automation and well-organized data lets each biologics experiment shape the next, shown through real examples. AI & computational design |
Selvita Kraków, Poland | |
Preclinical contract research organization supporting drug discovery and development studies. | Booth Exhibiting (no floor booth listed) Talk Wed Oct 14 17:10 Developability of antibodies: challenges and future directions Why many antibody drug candidates still fail late over poor stability or clumping, and how automated screening and AI could catch problems earlier. |
Supplier of single-use components for aseptic liquid transfer systems in pharmaceutical and biopharmaceutical manufacturing. | Booth Exhibiting at Booth 230 |
Adimab Lebanon, NH | |
Yeast-based antibody discovery and optimization platform that partners with biopharma companies on therapeutic antibody and bispecific programs. | Booth Exhibiting (no floor booth listed) Talk Wed Oct 14 12:10 Adimab: Multispecific Antibodies Beyond Monospecific Therapies Why single-target antibodies fall short for some patients, and how ready-made parts that bind T cells speed design of multi-target antibodies. |
ATUM Newark, CA | |
Gene synthesis, protein engineering and Leap-In transposase cell line development tools and services for biologics developers. | Booth Exhibiting at Booth 278 Talk Wed Oct 14 11:50 Overcoming Manufacturing Bottlenecks in Multispecific Design via Native Scaffold Engineering How keeping the natural antibody shape, with few mutations, helps multi-target antibodies assemble correctly and stay easy to make. |
Benchling San Francisco, CA | |
Cloud R&D software for biotech data and workflows, including tools for biologics and antibody discovery. | Booth Exhibiting at Booth 226 Talk Wed Oct 14 15:10 Benchling Biologics: AI Infrastructure for Modern Antibody Discovery Why years of antibody data rarely help machine learning, and how consistent naming and linked records let teams run design-and-test cycles faster. |
Develops a scalable platform for crystallizing biologic drugs in microgravity, targeting high-concentration, low-viscosity formulations. | Booth Exhibiting (no floor booth listed) |
Booth Exhibiting (no floor booth listed) Talk Tue Oct 13 15:10 Image-Based Monoclonality Assurance for Biotherapeutic Cell Lines: Evaluating Clone Outgrowth and Suspension Adaptation Following Single-Cell Isolation How images of single seeded cells help show regulators a production cell line grew from one cell, compared across three cell types. | |
Supplies cell culture consumables, bioprocess vessels and lab equipment for research and biomanufacturing. | Booth Exhibiting (no floor booth listed) Panel Tue Oct 13 15:10 Panel Discussion: From Research to GMP: Making MSC Manufacturing Reproducible at Scale How to grow mesenchymal stromal cells, a kind of stem cell, the same way batch after batch as production scales up. |
Cytiva Marlborough, MA | |
Provides a broad portfolio of technologies and expertise for developing and manufacturing therapies, including chromatography systems. | Booth Exhibiting at Booth 356 |
Makes elastomer components such as plungers and stoppers for injectable drug packaging and delivery systems. | Booth Exhibiting at Booth 270 Talk Thu Oct 15 11:40 Novel Plunger Solution to Meet Sensitive Biologics and Processability Needs for Subcutaneous Delivery Systems How to choose rubber plungers that seal, glide and protect thick, concentrated biologics that patients inject under their own skin. |
Ecolab's life sciences business, supplying Purolite chromatography resins and contamination-control products for biopharma manufacturing. | Booth Exhibiting (no floor booth listed) Talk Wed Oct 14 14:30 Impurity control in complex monoclonal antibody purification via next-generation resins How newer affinity resins, beads that grab antibodies during purification, can clean up complex antibody designs at commercial scale. |
Contract development and manufacturing organization for biologics, vaccines and advanced therapies. | Booth Exhibiting at Booth 408 Keynote Tue Oct 13 12:40 |
Genos Zagreb, Croatia | |
Glycomics company providing high-throughput, precision analysis of glycans. | Booth Exhibiting at Booth 411 Talk Wed Oct 14 17:30 CRISPR-Based Epigenome Editing: From Targeted DNA Methylation to the Development of a Modular Epi-Toolbox How a modular CRISPR toolkit adds or removes DNA methylation to turn genes down or up without changing the DNA sequence. |
genOway Lyon, France | |
Provides humanized mouse models and other preclinical models and solutions to bridge preclinical research and clinical success. | Booth Exhibiting at Booth 399 Talk Tue Oct 13 15:10 Advancing T‑Cell Engagers: Addressing Key Efficacy and Safety Challenges How mice with a human immune system test T cell engagers, tracking immune cells entering tumors and myeloid cells' role in cytokine release. |
Family-owned CRDMO combining preclinical research and clinical manufacturing of therapeutic proteins from mammalian cells at one site. | Booth Exhibiting at Booth 224 Talk Wed Oct 14 14:50 Designing Manufacturability into Multispecifics Early: How Integrated CRDMO De-risks Biologics Programs and Accelerates Development Why checking how easy complex biologics are to make before picking a final candidate leads to faster, cheaper, lower-risk development. |
Through its Specifica business, supplies Generation 3 antibody libraries for phage and yeast display discovery of drug-like antibodies. | Booth Exhibiting at Booth 290 Talk Tue Oct 13 17:30 Beyond recombinant proteins: therapeutic antibody discovery strategies for cells, GPCRs, and challenging targets How lab-made antibody libraries now rival animal immunization and find antibodies to hard targets like G protein-coupled receptors on live cells. |
Makes highly active recombinant proteins and enzymes for antibody discovery, immunotherapy, gene therapy and mRNA therapeutics. | Booth Exhibiting at Booth 284 Talk Tue Oct 13 14:50 From Complex Membrane Proteins to Emerging Targets: Unlocking New Frontiers in Antibody Discovery How showing full-length membrane proteins in virus-like particles and nanodiscs, tiny membrane patches, helps find antibodies to hard targets like ion channels. |
KBI Biopharma Durham, NC | |
Contract development and manufacturing organization for biologics, from cell line development to clinical and commercial production. | Booth Exhibiting at Booth 294 Talk Tue Oct 13 17:10 Smarter lead selection and faster representative material for early CMC studies How inserting genes with a transposase and growing stable cell pools helps teams pick lead molecules and make realistic early batches sooner. |
Malvern Panalytical Malvern, United Kingdom | |
Makes material characterization instruments, including light scattering systems for measuring biologics stability. | Booth Exhibiting at Booth 116 |
Biologics discovery company combining its LensAI bio-native AI with lab research for antibodies, peptides and vaccines. | Booth Exhibiting at Booth 184 Talk Wed Oct 14 17:10 How LensAI Uses a Biology-Native Context Layer in Drug Discovery How linking scattered biologics discovery data, from sequences to assay results, into one connected and traceable system lets AI reason across it. |
Harbour BioMed's discovery company, offering Harbour Mice antibody platforms (H2L2, HCAb) and discovery services for antibodies, multispecifics, ADCs and CAR-T binders. | Booth Exhibiting at Booth 424 Keynote Wed Oct 14 09:30 Novel Next-generation Multispecifics, CAR-Ts & ADCs from H2L2 & HCAb Harbour Mice® How mice that make human antibodies, including heavy-chain-only ones, are used to build multi-target antibodies, CAR-T cells and antibody–drug conjugates for cancer. Bispecifics & multispecificsADCs & armed antibodies |
Nuclera Cambridge, United Kingdom | |
Makes the eProtein Discovery benchtop system, which uses cell-free expression to give researchers rapid access to functional proteins for drug discovery. | Booth Exhibiting at Booth 114 Talk Tue Oct 13 14:30 Testing Engineered Antibodies at Scale: Cell-Free Screening of AI Designed Panels How making full antibodies without living cells quickly shows which AI-designed variants bind, closely matching slower tests in mammalian cells. |
Puerto Rico-based biologics CDMO offering development, manufacturing and flexible fill-finish capacity for sponsors seeking US-made biologics. | Booth Exhibiting (no floor booth listed) Panel Wed Oct 14 17:30 PANEL DISCUSSION: From Contract to Collaboration: Effective CDMO Strategies for Biopharma Manufacturing How drug makers and contract manufacturers can work as true partners, sharing process know-how and handling changes as production scales up. |
Instantly find 20 buyers from Festival of Biologics 2026 exhibitors
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Browse Festival of Biologics 2026 by
Organization type
Topic
- Antibody & protein engineering 67
- AI & computational design 38
- Bispecifics & multispecifics 13
- ADCs & armed antibodies 18
- Immunotherapy & oncology 44
- Cell & gene therapy 28
- Therapeutic vaccines 13
- Peptides & GLP-1 7
- Bioprocessing & manufacturing 87
- CMC, formulation & analytics 58
- Clinical development 45
- Regulation & market access 40
Exhibit hall
- Exhibitors 188
Everyone
Not affiliated with or endorsed by Terrapinn or the Festival of Biologics. Submit a correction